It's time to buy shares of this under-the-radar injectable delivery and beauty packaging maker with more than 30% upside potential, according to Jefferies. Analyst Daniel Rizzo upgraded shares of Aptargroup to a buy rating, saying that new pharmaceutical delivery products should drive 10% sales growth on a compound annual basis through 2027. Along with the upgrade, Rizzo boosted his price target by 39% to $215 a share, representing 33% upside from Friday's close. The firm also forecasts that the company can drive 7% to 11% pharmaceuticals sales growth over the next 10 years, given that 80% of its delivery systems are protected by intellectual property tools such as patents. "The stock is up ~30% YTD ... but as new products help earnings accelerate, we expect multiple expansion to help support another ~30% increase."

---

Persons: Daniel Rizzo, Rizzo Organizations: Jefferies, OTC Narcan, pharma Locations: Aptargroup, U.S